Immuron Limited (ANW.F)

0.0545 +0.0005 (+0.93%) As of 08:13AM CEST. Market open.

Immuron Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
Australia
61 3 9824 5254
https://www.immuron.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 6

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Steven George Lydeamore CPA, M.B.A.	Chief Executive Officer	281.61k	N/A	1968
Dr. Jerry Kanellos Ph.D.	Chief Operating Officer	174.78k	N/A	1961
Mr. Flavio Palumbo	Chief Commercial Officer	176.05k	N/A	1974
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO & Company Secretary	N/A	N/A	1959
Mr. David Lyon	Head of Marketing	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Corporate Governance

Immuron Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.